US litigation issues remain the firm's Achilles heel
The company had posted a net profit of Rs 1,342.50 crore for the corresponding period of the previous fiscal
After a 4-yr decline that erased 65% from the value of Sun, Shanghvi is preparing to bounce back
Shangvi feels the domestic market is big enough to accommodate both branded and unbranded medicines
The policy push comes as many generic drugmakers are still reeling from a brutal price war in the world's biggest drug market, the US.
As per media reports, the regulator is learnt to have found deficiencies relating to medicine quality, data collection, maintenance as well as quality control unit
The pharma company had reported a nearly four-fold jump in its consolidated net profit at Rs 1,241.85 crore for the third quarter of financial year 2018-19(FY18-19).
The company may also spend more on research and development (R&D) next year owing to clinical trials for new indications of its recently launched product Ilumya and others
The company had posted a net profit of Rs 321.57 crore for the corresponding period of the previous fiscal
Dilip Shanghvi clarifies stance on various allegations, claims mala fide campaign against him and firm
Sun Pharma in damage control mode after stock loses about 30% of its value since Sept due to corporate governance concerns
The move comes after its shares tumbled last week following reports about a complaint by a whistleblower to regulators relating to certain transactions involving the company and an executive director
The drug major said that its domestic formulations distribution shall be transitioned from Aditya Medisales, the current distributor, to a wholly-owned subsidiary of Sun Pharma.
Sun Pharma had last week asked India's capital markets regulator to look into a media report about an alleged complaint by a whistleblower
Here's a look at what technical charts indicate for the two buzzing stocks - L&T and Sun Pharma -
The stock recovered 8% from Friday's low after the Sun Pharma urged the markets regulator to examine the role of some media houses with regard to the allegations raised by the whistle-blower.
Pharma company's valuations have been hit by several issues resulting in the promoter losing nearly Rs 90,000 cr
Sun Pharma on Friday urged the markets regulator to examine the role of some media houses with regard to the allegations raised by the whistle-blower
Shares of Sun Pharma plummeted over 8 per cent that wiped out Rs 8,735 crore from its market valuation
According to a news report by financial news website Moneylife, huge transactions took place between Aditya Medisales and private Companies of Sun Pharma's promoters between 2014 and 2017